Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.

Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T.

JAMA Ophthalmol. 2014 Nov;132(11):1317-26. doi: 10.1001/jamaophthalmol.2014.2333. Review.

PMID:
25058694
2.

Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.

Ueta T, Noda Y, Toyama T, Yamaguchi T, Amano S.

Ophthalmology. 2014 Nov;121(11):2193-203.e1-7. doi: 10.1016/j.ophtha.2014.05.022. Epub 2014 Jul 12. Review.

PMID:
25023760
3.

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.

Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G.

Cochrane Database Syst Rev. 2014 Sep 15;(9):CD011230. doi: 10.1002/14651858.CD011230.pub2. Review.

4.

Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.

Avery RL, Gordon GM.

JAMA Ophthalmol. 2016 Jan;134(1):21-9. doi: 10.1001/jamaophthalmol.2015.4070. Review.

PMID:
26513684
5.

Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.

Zhou S, Gao J, Xu X.

Clin Exp Ophthalmol. 2014 Sep-Oct;42(7):637-49. doi: 10.1111/ceo.12286. Epub 2014 Jan 27.

PMID:
24330277
6.
7.

Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.

Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA.

Br J Ophthalmol. 2015 Feb;99(2):141-6. doi: 10.1136/bjophthalmol-2014-305149. Epub 2014 Jun 11. Review.

PMID:
25271911
8.

Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.

Tolentino M.

Surv Ophthalmol. 2011 Mar-Apr;56(2):95-113. doi: 10.1016/j.survophthal.2010.08.006. Review.

PMID:
21335144
9.

Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.

Campbell RJ, Bell CM, Paterson JM, Bronskill SE, Moineddin R, Whitehead M, Gill SS.

Ophthalmology. 2012 Aug;119(8):1604-8. doi: 10.1016/j.ophtha.2012.05.028. Epub 2012 Jun 19.

PMID:
22717458
10.

A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.

van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS.

Retina. 2011 Sep;31(8):1449-69. doi: 10.1097/IAE.0b013e3182278ab4. Review.

PMID:
21817960
11.

Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration.

Dedania VS, Bakri SJ.

Curr Opin Ophthalmol. 2016 May;27(3):224-43. doi: 10.1097/ICU.0000000000000257. Review.

PMID:
26871657
12.

Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.

Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P.

Ophthalmology. 2012 Apr;119(4):802-9. doi: 10.1016/j.ophtha.2011.12.005. Epub 2012 Feb 1.

PMID:
22301066
13.

Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials.

Zarbin MA, Dunger-Baldauf C, Haskova Z, Koovejee P, Mousseau MC, Margaron P, Snow H, Beaumont PE, Staurenghi G, Francom S.

JAMA Ophthalmol. 2017 May 1;135(5):424-431. doi: 10.1001/jamaophthalmol.2017.0455.

PMID:
28384675
14.

Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism.

Schlenker MB, Thiruchelvam D, Redelmeier DA.

Am J Ophthalmol. 2015 Sep;160(3):569-580.e5. doi: 10.1016/j.ajo.2015.06.011. Epub 2015 Jun 23.

PMID:
26116264
15.

Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema.

Zhang Y, Yao Z, Kaila N, Kuebler P, Visich J, Maia M, Tuomi L, Ehrlich JS, Rubio RG, Campochiaro PA.

Ophthalmology. 2014 Nov;121(11):2237-46. doi: 10.1016/j.ophtha.2014.05.012. Epub 2014 Jul 4.

PMID:
25001159
16.

Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.

[No authors listed]

Prescrire Int. 2015 Sep;24(163):201-4. Review.

PMID:
26417625
17.

Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.

Jiang S, Park C, Barner JC.

J Clin Pharm Ther. 2014 Jun;39(3):234-9. doi: 10.1111/jcpt.12146. Epub 2014 Mar 17. Review.

PMID:
24635444
18.

Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review.

Abouammoh MA.

Can J Ophthalmol. 2013 Aug;48(4):317-23. doi: 10.1016/j.jcjo.2013.03.004. Review. Erratum in: Can J Ophthalmol. 2013 Oct;48(5):451.

PMID:
23931473
19.

Ranibizumab and retinal vein occlusion. Too many outstanding questions.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):207.

PMID:
23016250
20.

Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.

Abouammoh M, Sharma S.

Curr Opin Ophthalmol. 2011 May;22(3):152-8. doi: 10.1097/ICU.0b013e32834595d0. Review.

PMID:
21483262

Supplemental Content

Support Center